ADC Therapeutics S.A.
ADCT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $193 | $136 | $300 | $1,550 |
| - Cash | $251 | $279 | $326 | $467 |
| + Debt | $123 | $124 | $117 | $102 |
| Enterprise Value | $65 | -$19 | $91 | $1,186 |
| Revenue | $71 | $70 | $210 | $34 |
| % Growth | 1.8% | -66.9% | 518.9% | – |
| Gross Profit | $65 | $67 | $207 | $33 |
| % Margin | 91.6% | 96.4% | 98.4% | 95.9% |
| EBITDA | -$103 | -$146 | -$108 | -$231 |
| % Margin | -144.9% | -209.6% | -51.3% | -679.7% |
| Net Income | -$158 | -$240 | -$157 | -$230 |
| % Margin | -222.8% | -345.1% | -74.9% | -678.2% |
| EPS Diluted | -1.62 | -2.94 | -1.99 | -3 |
| % Growth | 44.9% | -47.7% | 33.7% | – |
| Operating Cash Flow | -$124 | -$119 | -$138 | -$233 |
| Capital Expenditures | -$1 | -$3 | -$1 | -$6 |
| Free Cash Flow | -$125 | -$122 | -$139 | -$240 |